Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.82 USD | -4.46% | +2.26% | +52.88% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.88% | 2.46B | |
+75.69% | 12.57B | |
-24.12% | 7.4B | |
+10.90% | 6.9B | |
+20.88% | 5.79B | |
-16.83% | 4.86B | |
+19.43% | 4.27B | |
-18.60% | 3.96B | |
-24.00% | 2.87B | |
0.00% | 2.04B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Insider Sell: Novocure